Juvenile Idiopathic Arthritis News and Research

RSS
Juvenile idiopathic arthritis (JIA) is the name given to a group of conditions characterized by joint inflammation or arthritis, occurring first before the age of 16.
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Report: Britons at risk of long-term disability, reduced life expectancy due to delays in treatment services

Report: Britons at risk of long-term disability, reduced life expectancy due to delays in treatment services

TTR protein causes autoimmune reaction in joints of juvenile idiopathic arthritis patients

TTR protein causes autoimmune reaction in joints of juvenile idiopathic arthritis patients

Aggregated forms of transthyretin can trigger JIA development

Aggregated forms of transthyretin can trigger JIA development

People with viral infections and identical gene mutations may be prone to hyperinflammatory disorder

People with viral infections and identical gene mutations may be prone to hyperinflammatory disorder

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Cleveland Clinic Children's to host second annual Pediatric Innovation Summit

Cleveland Clinic Children's to host second annual Pediatric Innovation Summit

Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement procedure alleviates pain, improves function in young JIA patients

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

BRI signs license agreement with SOBI for Kineret (anakinra)

BRI signs license agreement with SOBI for Kineret (anakinra)

Total hip replacement: An excellent option for younger patients with juvenile idiopathic arthritis

Total hip replacement: An excellent option for younger patients with juvenile idiopathic arthritis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Timely diagnosis and treatment important to combat juvenile arthritis

Timely diagnosis and treatment important to combat juvenile arthritis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Arthritis Foundation raises public awareness about juvenile arthritis

Arthritis Foundation raises public awareness about juvenile arthritis

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014